Bonet H, Manez R, Kramer D, Wright H I, Gavaler J S, Baddour N, Van Thiel D H
Oklahoma Transplantation Institute, Baptist Medical Center of Oklahoma, Oklahoma City 73112-4481.
Alcohol Clin Exp Res. 1993 Oct;17(5):1102-6. doi: 10.1111/j.1530-0277.1993.tb05671.x.
From January 1986 through December 1991, a total of 221 patients with alcoholic liver disease received liver transplantation. In 147 of these cases, complete pretransplant histopathologic, demographic, and laboratory data (minimum of CBC, AST, ALT, total bilirubin, albumin, and prothrombin time) were available for review. Forty-five (30%) of the 147 recipients had alcoholic hepatitis plus cirrhosis (AH), whereas 70% had cirrhosis (CIRR) alone. Age and sex were similar in the subgroups, but the patients with CIRR had a greater AST/ALT ratio, longer protime, and lower platelet count (all p < 0.01). Coexistent hepatitis B (4.7%) or hepatitis C (4.1%) was similar in both groups. Current survival is 80% for patients with AH and 84% for those with CIRR (NS). Overall, survivors were younger (43.4 +/- 1.7 years) than nonsurvivors (53.6 +/- 3.2) (p < 0.01), an age influence that was significant in the CIRR group (p < 0.01) but not in the AH group. Inexplicably, the AST/ALT ratio was greater in AH survivors (1.5 +/- 0.2) than it was in nonsurvivors (0.4 +/- 0.1) (p < 0.01). In patients with CIRR, the platelet count was greater in survivors (252 +/- 29 vs. 86 +/- 11 x 10(9) cells/liter). The data support the clinical impression that patients with chronic decompensated cirrhosis referred for liver transplantation had more severe complications of their liver disease than did those with AH. Survival in both subgroups was similar, but overall the survivors are nearly a decade younger than the nonsurvivors.(ABSTRACT TRUNCATED AT 250 WORDS)
从1986年1月至1991年12月,共有221例酒精性肝病患者接受了肝移植。其中147例患者有完整的移植前组织病理学、人口统计学和实验室数据(至少包括全血细胞计数、谷草转氨酶、谷丙转氨酶、总胆红素、白蛋白和凝血酶原时间)可供回顾。147例受者中,45例(30%)患有酒精性肝炎合并肝硬化(AH),而70%仅患有肝硬化(CIRR)。各亚组的年龄和性别相似,但CIRR患者的谷草转氨酶/谷丙转氨酶比值更高、凝血时间更长且血小板计数更低(均p<0.01)。两组中乙肝(4.7%)或丙肝(4.1%)的合并感染情况相似。AH患者的当前生存率为80%,CIRR患者为84%(无显著差异)。总体而言,存活者(43.4±1.7岁)比非存活者(53.6±3.2岁)年轻(p<0.01),年龄影响在CIRR组显著(p<0.01),但在AH组不显著。令人费解的是,AH存活者的谷草转氨酶/谷丙转氨酶比值(1.5±0.2)高于非存活者(0.4±0.1)(p<0.01)。在CIRR患者中,存活者的血小板计数更高(252±29对86±11×10⁹个细胞/升)。这些数据支持了临床印象,即因慢性失代偿性肝硬化而接受肝移植的患者比AH患者有更严重的肝脏疾病并发症。两个亚组的生存率相似,但总体而言,存活者比非存活者年轻近十岁。(摘要截短至250字)